# Midodrine Plus Albumin Versus Midodrine Alone to Prevent Cirrhosis Related Complications in Children With Cirrhosis and Ascites

> **NCT06091345** · NA · COMPLETED · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 61 (actual)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **DRUG:** Midodrine
- **BIOLOGICAL:** albumin
- **OTHER:** Standard Medical Treatment

## Key facts

- **NCT ID:** NCT06091345
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-22
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06091345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06091345, "Midodrine Plus Albumin Versus Midodrine Alone to Prevent Cirrhosis Related Complications in Children With Cirrhosis and Ascites". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06091345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*